MAPT and Alzheimer disease: For this preregistered study, we included 100 older adults who were amyloid- and tau-negative using CSF and PET measurements to investigate “normal” aging, and 70 older adults who had longitudinal CSF data available to investigate functional changes related to early AD pathology.